viru
junv
sever
clade
b
new
world
arenavirus
caus
human
diseas
rang
mild
febril
ill
sever
viral
hemorrhag
fever
hf
virus
pose
signific
threat
nation
secur
safe
effect
therapi
limit
outsid
argentina
immun
plasma
standard
care
treat
junv
infect
case
argentin
hf
methodsan
vitro
screen
chemtura
librari
identifi
sever
compound
activ
tacarib
viru
tcrv
clade
b
arenaviru
close
relat
junv
compound
phenol
dibenzylsulfid
pursu
addit
vitro
studi
evalu
mous
tcrv
infect
model
found
act
earli
intermedi
stage
tcrv
replic
cycl
micromolar
rang
activ
confirm
viru
yield
reduct
assay
tcrv
junv
although
intraperiton
twice
daili
treatment
regimen
found
highli
effect
start
hour
prior
tcrv
challeng
mice
postexposur
treatment
initi
day
infect
efficaci
interestingli
despit
preexposur
treatment
success
reduc
serum
tissu
viru
titer
acut
infect
moreov
elicit
ascit
fluid
accumul
mice
well
independ
infect
conclusionsour
find
suggest
may
alter
host
respons
tcrv
infect
mice
way
limit
pathogenesi
therebi
protect
mice
otherwis
lethal
infect
absenc
measur
reduct
viral
burden
sever
clade
b
new
world
arenavirus
nwa
caus
diseas
rang
mild
febril
ill
fatal
viral
hemorrhag
fever
hf
human
arenavirus
transmit
human
typic
contact
rodent
reservoir
inhal
aerosol
viru
pass
excreta
viru
junv
etiolog
agent
argentin
hf
diseas
evolv
sever
hemorrhag
neurolog
manifest
patient
fatal
rate
case
requir
medic
attent
nation
institut
allergi
infecti
diseas
classifi
junv
pathogen
clade
b
virus
categori
prioriti
pathogen
pose
signific
risk
nation
secur
public
health
nonspecif
antivir
ribavirin
licens
drug
avail
treat
arenavir
hf
emerg
provis
howev
limit
data
support
use
ribavirin
treat
sever
infect
new
world
hf
arenavirus
addit
ribavirin
also
associ
toxic
form
revers
hemolyt
anemia
human
teratogen
effect
observ
rodent
threat
intent
releas
highli
pathogen
arenavirus
terrorist
group
combin
risk
natur
occur
outbreak
certain
region
world
underlin
need
develop
safe
effect
therapi
tacarib
viru
tcrv
clade
b
arenaviru
close
relat
junv
pathogen
clade
b
arenavirus
consid
frank
human
pathogen
consequ
earli
stage
drug
discoveri
research
greatli
facilit
tcrv
handl
biosafeti
level
laboratori
rather
stringent
maximum
contain
requir
junv
hf
arenavirus
end
other
previous
report
use
cell
culturebas
cytopath
tcrv
infect
assay
identifi
evalu
promis
antiarenaviru
compound
object
discov
develop
novel
antiarenaviru
compound
use
tcrv
infect
assay
screen
chemtura
librari
wherein
identifi
sever
compound
antivir
activ
nwa
report
one
compound
phenol
dibenzylsulfid
refer
consist
demonstr
activ
tcrv
nwa
rigor
viru
yield
reduct
assay
studi
employ
tcrv
mous
infect
model
base
challeng
type
ii
interferon
ifn
receptor
knockout
mice
reveal
activ
preexposur
prophylaxi
postexposur
intervent
remark
pretreat
reduc
viral
titer
elicit
accumul
ascit
fluid
suggest
immun
mediat
alter
host
respons
may
confer
observ
protect
effect
ifn
receptor
defici
mice
bred
utah
state
univers
specif
pathogen
free
condit
fed
irradi
mous
chow
autoclav
water
ad
libitum
five
tenweek
old
mice
use
experi
anim
procedur
use
studi
compli
guidelin
set
usda
utah
state
univers
anim
care
use
committe
tcrv
strain
trvl
obtain
american
type
cultur
collect
atcc
manassa
va
viru
stock
use
vitro
experi
deriv
clarifi
cell
lysat
produc
three
passag
vero
african
green
monkey
kidney
cell
viru
stock
use
mous
studi
clarifi
liver
homogen
mice
challeng
vitro
stock
junv
candid
strain
obtain
dr
robert
tesh
world
refer
center
emerg
virus
arbovirus
univers
texa
medic
branch
galveston
tx
candid
viru
use
passag
epitheli
african
green
monkey
kidney
cell
vero
cell
viru
picv
strain
provid
dr
david
gangemi
clemson
univers
clemson
sc
picv
use
passag
hamster
vero
cell
provid
chemtura
corpor
guelph
ontario
canada
vitro
activ
experi
dissolv
dmso
dilut
steril
minim
essenti
medium
mem
thermo
scientif
hyclon
logan
ut
final
dmso
concentr
less
efficaci
studi
mice
dissolv
ethanol
dilut
sigmaaldrich
st
loui
mo
salin
ce
ratio
ribavirin
suppli
icn
pharmaceut
inc
costa
mesa
ca
prepar
steril
salin
treatment
administ
intraperiton
ip
inject
ml
vero
cell
obtain
atcc
maintain
mem
supplement
nahco
fetal
bovin
serum
fb
hyclon
thermo
scientif
virus
titrat
mem
cultur
medium
contain
fb
identifi
optim
infecti
dose
produc
maxim
cytopath
effect
cpe
less
day
vari
concentr
ribavirin
posit
control
ad
test
well
contain
confluent
vero
cell
time
infect
virus
multipl
infect
moi
approxim
plate
incub
co
virusinfect
control
well
observ
maxim
viral
cpe
day
time
plate
process
determin
viru
yield
reduct
vyr
previous
describ
concentr
compound
reduc
viru
yield
log
ec
determin
regress
analysi
toxic
determin
done
parallel
compound
ad
uninfect
vero
cell
drug
concentr
reduc
cell
viabil
cc
also
determin
regress
analysi
select
index
si
valu
calcul
cc
ec
vyr
assay
timeofaddit
assay
subconflu
vero
cell
monolay
plate
inocul
tcrv
moi
incub
co
hour
triplic
well
incub
vari
concentr
mem
cultur
medium
h
rel
time
infect
follow
h
treatment
period
media
replac
new
growth
media
devoid
plate
frozen
h
postinfect
viral
cpe
determin
calcul
cell
cultur
infecti
dose
ccid
previous
describ
experi
mice
sort
treatment
group
mice
minim
gender
age
differ
challeng
ip
ml
tcrv
prepar
mem
ribavirin
ce
vehicl
placebo
treatment
administ
ip
twice
daili
achiev
state
mgkgday
dose
durat
treatment
experi
day
prophylact
efficaci
experi
treatment
start
h
prior
challeng
ccid
tcrv
evalu
postexposur
efficaci
treatment
initi
day
challeng
ccid
tcrv
increas
ccid
achiev
uniform
lethal
observ
lower
dose
two
experi
group
anim
sacrif
day
infect
analysi
serum
tissu
viru
titer
remain
anim
observ
week
morbid
mortal
bodi
weight
assess
everi
day
start
day
rel
time
challeng
viru
titer
assay
use
infecti
endpoint
dilut
cell
cultur
assay
previous
describ
briefli
specif
volum
tissu
homogen
serum
serial
dilut
ad
triplic
quadrupl
well
vero
cell
monolay
micropl
viral
cpe
determin
incub
endpoint
calcul
describ
assay
detect
limit
design
lowest
point
axi
viru
titer
graph
twoway
analysi
varianc
anova
bonferroni
posttest
use
analyz
timeofaddit
data
mantelcox
logrank
test
use
analysi
kaplanmei
surviv
curv
oneway
anova
newmankeul
posttest
perform
analyz
viru
titer
differ
statist
evalu
done
use
graphpad
softwar
la
jolla
ca
follow
initi
hit
phenol
dibenzylsulfid
structur
shown
figur
tcrv
infect
screen
chemtura
librari
inhibitori
effect
compound
confirm
use
rigor
secondari
test
assay
shown
tabl
activ
rang
tcrv
junv
picv
vyr
assay
si
valu
rang
notabl
tcrv
inhibit
doserespons
curv
shallow
compar
ribavirin
figur
curv
repres
cell
cytotox
compound
rel
ribavirin
shown
figur
inact
vaccin
strain
rift
valley
fever
viru
dengu
viru
serotyp
west
nile
viru
yellow
fever
viru
venezuelan
equin
enceph
viru
sar
coronaviru
sever
strain
influenza
viru
primari
test
data
shown
result
demonstr
specif
toward
arenavirus
timeofaddit
studi
conduct
provid
insight
mechan
inhibit
arenaviru
infect
vero
cell
monolay
treat
addit
variou
time
prior
tcrv
infect
reduct
viru
product
rel
untreat
cultur
assess
h
postinfect
greatest
inhibit
tcrv
replic
observ
cell
pretreat
diminish
doserespons
activ
seen
h
treatment
time
figur
signific
inhibit
seen
cell
treat
hour
infect
previous
report
h
requir
detect
infecti
tcrv
particl
vero
cultur
supernat
suggest
viru
detect
h
cultur
initi
infect
cycl
thu
find
suggest
effect
target
earli
intermedi
stage
viru
life
cycl
inhibit
viru
adsorpt
like
consid
antiarenaviru
activ
cell
cultur
next
evalu
compound
tcrv
mous
infect
model
first
efficaci
studi
select
treatment
regimen
consist
daili
dose
mgkg
administ
ip
inject
everi
h
start
h
prior
tcrv
challeng
dose
well
toler
uninfect
mice
initi
mean
toler
dose
studi
data
shown
seen
figur
mgkgday
dose
highli
effect
protect
infect
mice
mortal
compar
survivor
placebo
group
receiv
ce
vehicl
signific
differ
surviv
curv
analysi
mean
day
death
comparrison
group
treat
mgkg
day
versu
placebo
unexpectedli
ribavirin
routin
includ
posit
control
fail
protect
tcrvchalleng
mice
daili
total
dose
mgkgday
previous
report
effect
aforment
studi
ribavirin
given
daili
mgkg
dose
wherea
present
studi
divid
two
mgkg
dose
everi
hour
conceiv
larger
bolu
dose
reach
effect
concentr
critic
area
therebi
result
measur
protect
effect
ad
stress
due
twice
daili
inject
may
also
contribut
ineffect
observ
initi
experi
signific
protect
afford
prophylact
treatment
first
experi
second
studi
includ
higher
dose
compound
addit
anim
determin
reduct
viru
titer
conduct
mice
treat
highest
dose
mgkgday
surviv
tcrv
challeng
compar
placebo
group
figur
addit
signific
protect
surviv
also
observ
dose
mgkgday
confirm
result
first
experi
mgkgday
dose
half
mice
receiv
higher
dose
ribavirin
given
second
experi
surviv
infect
howev
due
surviv
rate
placebo
group
differ
signific
dose
mg
kgday
also
evalu
parallel
uninfect
anim
weight
loss
observ
mice
ultim
recov
follow
cessat
treatment
data
shown
gener
mean
group
mous
weight
drop
dramat
day
day
figur
mice
receiv
mgkgday
dose
start
recov
day
mice
treat
mgkgday
dose
began
show
collect
increas
weight
day
day
respect
placeboand
ribavirintr
mice
greatest
mean
weight
loss
end
observ
period
ribavirin
group
actual
show
brief
improv
prior
second
decreas
anim
weight
howev
variabl
weight
chang
pronounc
end
experi
due
continu
ill
mice
other
recoveri
predetermin
cohort
infect
treat
mice
sacrif
day
analysi
serum
tissu
viru
titer
unexpectedli
significantli
higher
serum
liver
lung
titer
present
mice
compar
placebotr
anim
effect
appear
dosedepend
howev
effect
spleen
titer
figur
f
ribavirin
reduc
viru
titer
serum
liver
spleen
gener
viru
titer
placebotr
anim
lower
expect
like
due
diseas
develop
slowli
particular
experi
consid
surviv
data
increas
viru
burden
mice
treat
unexpect
notabl
sacrific
observ
larg
volum
ascit
fluid
fibrou
materi
surround
liver
effect
dosedepend
mice
mgkgday
treatment
group
clearli
ascit
fluid
accumul
data
shown
phenomenon
restrict
group
ribavirin
placebo
anim
unremark
upon
open
periton
caviti
tissu
collect
suggest
ip
inject
caus
fluid
accumul
confirm
preexposur
prophylact
efficaci
next
evalu
abil
protect
tcrvchalleng
mice
administ
start
day
postexposur
initi
treatment
day
base
previou
data
suggest
day
viru
first
observ
sleen
tcrv
infect
would
allow
evalu
compound
prior
appear
substanti
viral
titer
due
limit
amount
compound
evalu
dose
mgkgday
contrast
efficaci
observ
given
preexposur
treatment
prevent
mortal
administ
infect
figur
ribavirin
effect
postexposur
collect
ribavirin
data
mous
experi
suggest
shift
treatment
schedul
mice
receiv
drug
day
infect
experi
oppos
day
experi
dramat
improv
surviv
possibl
allow
immun
system
respond
natur
progress
viru
initi
day
result
better
neutral
viru
combin
ribavirin
treatment
extend
cours
infect
protect
mice
lethal
tcrv
challeng
effect
delay
treatment
reduc
viral
titer
also
evalu
day
subset
mice
infect
treat
parallel
observ
mortal
ineffect
reduc
viral
titer
howev
contrast
second
experi
viral
load
group
significantli
elev
compar
placebo
group
figur
consist
surviv
data
figur
dramat
reduct
viru
titer
observ
ribavirin
signific
reduct
serum
liver
figur
c
one
death
occur
ribavirin
group
day
infect
prior
time
sacrific
result
fewer
anim
analysi
serum
tissu
viru
titer
occur
prior
would
expect
death
due
viru
infect
anim
believ
die
complic
notabl
product
ascit
fluid
seen
previou
experi
mice
confirm
harvest
tissu
infect
mice
moreov
uninfect
anim
also
ascit
fluid
accumul
peritoneum
suggest
compound
alon
induc
inflammatori
reaction
site
treatment
present
studi
describ
identif
phenol
dibenzylsulfid
vitro
activ
tcrv
junv
prophylact
activ
mous
model
tcrv
infect
appar
specif
arenavirus
cell
cultur
may
due
inhibit
host
cell
function
specif
support
arenavir
replic
precis
mechan
inhibit
replic
cell
cultur
clear
timeofaddit
studi
indic
earli
intermedi
step
viru
life
cycl
disrupt
particular
treatment
cell
prior
viru
infect
caus
viru
inhibit
suggest
may
attach
cell
block
subsequ
viru
adsorpt
case
previous
report
dibenzamido
molecul
inhibit
cytomegaloviru
adsorpt
cell
studi
would
need
perform
valid
hypothesi
interestingli
despit
highli
reproduc
inhibitori
effect
cell
cultur
experi
compound
fail
reduc
viremia
tissu
viral
load
mice
similar
disconnect
report
previous
aristeromycin
deriv
abl
inhibit
viral
replic
cellbas
arenaviru
assay
mice
infect
tcrv
notabl
howev
elicit
ascit
effect
pretreat
therapeut
administ
start
day
viru
challeng
differ
suggest
act
distinct
manner
case
hypothes
periton
caviti
fluid
elicit
ip
treatment
indic
inflammatori
respons
may
alter
diseas
process
way
promot
surviv
mice
treatment
begin
prior
challeng
despit
reduct
system
tissu
viral
titer
measur
day
infect
benefici
effect
lost
treatment
began
challeng
still
evid
ascit
fluid
accumul
mice
protect
lethal
tcrv
infect
second
pretreat
efficaci
experi
actual
found
significantli
higher
serum
liver
lung
titer
mice
compar
placebo
group
presum
given
prior
infect
chang
result
inflammatori
respons
enhanc
product
viru
perhap
recruit
specif
target
cell
amplifi
viru
amelior
host
diseas
process
like
contribut
demis
anim
treatment
initi
tcrv
infect
efficaci
compound
lost
increas
viru
titer
rel
placebo
treatment
group
longer
observ
altern
explan
higher
titer
mice
second
preexposur
treatment
experi
could
placebo
group
may
atyp
lower
viral
titer
usual
unfortun
suffici
test
compound
avail
valid
whether
elev
viral
titer
pretreat
condit
clear
reduc
viral
titer
treat
anim
present
limit
option
treatment
sever
arenavir
infect
despit
activ
research
toward
identifi
new
treatment
counter
arenavir
hf
syndrom
limit
number
therapi
evalu
anim
model
although
efficaci
administ
prophylact
question
whether
develop
compound
antiarenaviru
therapi
warrant
sinc
activ
vitro
modest
activ
administ
prior
infect
treatment
associ
reduct
viral
titer
excess
fluid
recruit
periton
caviti
link
ip
administr
compound
nevertheless
find
report
describ
novel
antivir
scaffold
underscor
challeng
associ
translat
vitro
result
anim
mice
n
drug
treatment
group
n
placebo
group
treat
ip
twice
daili
day
indic
amount
ribavirin
ce
vehicl
placebo
start
h
prior
challeng
ccid
tcrv
observ
day
p
compar
ce
placebotr
anim
surviv
outcom
mice
n
drug
treatment
group
n
placebo
group
treat
ip
twice
daili
day
indic
dose
ribavirin
placebo
start
h
prior
challeng
ccid
tcrv
b
individu
mous
weight
measur
interv
efficaci
studi
repres
group
mean
standard
deviat
percent
chang
weight
rel
start
weight
day
challeng
group
mice
n
per
drug
treatment
group
n
placebo
group
treat
challeng
parallel
observ
morbid
mortal
sacrif
day
post
infect
analysi
c
serum
liver
e
lung
f
spleen
viral
titer
one
mous
mgkg
group
succumb
prior
time
sacrific
uniqu
symbol
use
treatment
group
repres
valu
anim
across
tissu
p
p
p
compar
anim
receiv
placebo
mice
n
treatment
group
n
placebo
group
treat
ip
inject
indic
dose
ribavirin
placebo
twice
daili
day
start
day
challeng
ccid
tcrv
percent
surviv
shown
mice
n
per
group
treat
parallel
anim
observ
mortal
sacrif
day
post
infect
analysi
b
serum
c
liver
spleen
viru
titer
uniqu
symbol
treatment
group
repres
valu
anim
across
paramet
p
compar
anim
receiv
placebo
